Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02095834 | Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04702503 | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 1 | 5 | Moleculin Biotech, Inc.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT01169636 | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT00424983 | Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00622258 | A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00503451 | A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT00532389 | Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT00532675 | Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01456689 | A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02144038 | Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT02160951 | Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies | completed | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01275209 | Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma(LIFT) | completed | Phase 1 | 1 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 8, 2020 | clinicaltrials |
| NCT02581878 | Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma | completed | Phase 1 | 21 | BayerINDUSTRY | 2 | Nov 25, 2020 | clinicaltrials |
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | completed | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02504359 | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | completed | Phase 1 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | completed | Phase 1 | 66 | miRagen Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00691210 | Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies(SAHA) | completed | Phase 1 | 40 | Columbia UniversityOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT01572519 | A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 21 | Janssen Research & Development, LLCINDUSTRY | 2 | Nov 20, 2020 | clinicaltrials |
| NCT00642954 | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | completed | Phase 1 | 31 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 18, 2020 | clinicaltrials |
| NCT02181218 | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01155583 | Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT02852837 | Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy | completed | Phase 1 | 50 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 16, 2020 | clinicaltrials |
| NCT03688152 | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 9 | Incyte CorporationINDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | completed | Phase 1 | 27 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT02335983 | Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma | completed | Phase 1 | 107 | AmgenINDUSTRY | 1 | Nov 6, 2020 | clinicaltrials |
| NCT00966693 | Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00389051 | A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Oct 22, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02477215 | Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 38 | Parameswaran HariOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02541565 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma | completed | Phase 1 | 30 | University of WashingtonOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02100657 | Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 | 39 | PharmaMarINDUSTRY | 2 | Oct 12, 2020 | clinicaltrials |
| NCT01248923 | A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 55 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00469209 | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01570387 | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Boston Medical CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01842308 | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01593696 | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | completed | Phase 1 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2020 | clinicaltrials |
| NCT02343536 | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | completed | Phase 1 | 59 | CelgeneINDUSTRY | 1 | Aug 28, 2020 | clinicaltrials |
| NCT01561833 | A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients | completed | Phase 1 | 12 | Yale UniversityOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01403948 | BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 3 | Aug 11, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 11, 2021source: clinicaltrials